Anteris Technologies (AU:AVR) has released an update.
Anteris Technologies Ltd has successfully raised $30 million by issuing 1,916,000 new shares at $16 each to institutional and sophisticated investors, including a payment for services to Evolution Capital Pty Ltd. This significant capital injection will support the Australian-based company’s efforts in developing and commercializing advanced medical devices for structural heart disease, including their innovative DurAVR® transcatheter heart valve which features unique bioengineered tissue technology.
For further insights into AU:AVR stock, check out TipRanks’ Stock Analysis page.
